MX2019003726A - Metodos para tratar fibroides uterinos y endometriosis. - Google Patents

Metodos para tratar fibroides uterinos y endometriosis.

Info

Publication number
MX2019003726A
MX2019003726A MX2019003726A MX2019003726A MX2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A MX 2019003726 A MX2019003726 A MX 2019003726A
Authority
MX
Mexico
Prior art keywords
subject
methods
endometriosis
reducing
uterine fibroids
Prior art date
Application number
MX2019003726A
Other languages
English (en)
Spanish (es)
Inventor
Hibberd Mark
Reddy Rajasekhar Vijaykumar
Mark Johnson Brendan
Seely Lynn
N Mudd Paul Jr
Wollowitz Susan
Tanimoto Masataka
Vasant Sukhatme Mayukh
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60915460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003726(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of MX2019003726A publication Critical patent/MX2019003726A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Surgical Instruments (AREA)
MX2019003726A 2016-09-30 2017-09-29 Metodos para tratar fibroides uterinos y endometriosis. MX2019003726A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662402034P 2016-09-30 2016-09-30
US201662402055P 2016-09-30 2016-09-30
US201662402150P 2016-09-30 2016-09-30
US201762492839P 2017-05-01 2017-05-01
US201762528409P 2017-07-03 2017-07-03
PCT/EP2017/074907 WO2018060501A2 (en) 2016-09-30 2017-09-29 Methods of treating uterine fibroids and endometriosis

Publications (1)

Publication Number Publication Date
MX2019003726A true MX2019003726A (es) 2019-09-26

Family

ID=60915460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019003726A MX2019003726A (es) 2016-09-30 2017-09-29 Metodos para tratar fibroides uterinos y endometriosis.

Country Status (24)

Country Link
US (4) US11033551B2 (https=)
EP (2) EP3518933B2 (https=)
JP (1) JP7043503B2 (https=)
CN (1) CN110312512B (https=)
AU (2) AU2017336363B2 (https=)
BR (1) BR112019006227A2 (https=)
CA (1) CA3038879A1 (https=)
CY (1) CY1125254T1 (https=)
DK (1) DK3518933T4 (https=)
ES (2) ES2912929T5 (https=)
FI (1) FI3518933T4 (https=)
HR (1) HRP20220708T4 (https=)
HU (2) HUE072130T2 (https=)
IL (2) IL300580B2 (https=)
LT (1) LT3518933T (https=)
MD (1) MD3518933T4 (https=)
MX (1) MX2019003726A (https=)
NZ (1) NZ752916A (https=)
PL (2) PL4094766T3 (https=)
PT (1) PT3518933T (https=)
RS (1) RS63300B2 (https=)
SI (1) SI3518933T2 (https=)
SM (1) SMT202200254T1 (https=)
WO (1) WO2018060501A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
MA46361A (fr) 2016-09-30 2021-03-31 Myovant Sciences Gmbh Traitement du cancer de la prostate
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
KR102884301B1 (ko) 2017-06-05 2025-11-11 깃세이 야쿠힌 고교 가부시키가이샤 자궁 근종을 치료하고 월경혈량을 감소시키기 위한 고나도트로핀 방출 호르몬 길항제 투약 요법
CN112261942A (zh) * 2018-04-19 2021-01-22 艾伯维公司 治疗重度月经出血的方法
CA3117092A1 (en) 2018-10-29 2020-05-07 ObsEva S.A. Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis
RU2711658C1 (ru) * 2019-04-16 2020-01-20 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения наружного генитального эндометриоза
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
CN114466665A (zh) * 2019-08-08 2022-05-10 奥布赛瓦股份公司 用于治疗雌激素依赖性病症的组合物和方法
WO2021069700A1 (en) * 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021168040A1 (en) * 2020-02-19 2021-08-26 Aspira Women's Health Inc. Compositions for endometriosis assessment having improved specificity
CN113384581B (zh) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 一种包含促性腺激素释放激素拮抗剂的药物组合物
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
JP2024540922A (ja) 2021-10-18 2024-11-06 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
WO2024015934A2 (en) * 2022-07-13 2024-01-18 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of diagnostic screening and early detection of adenomyosis
TW202428262A (zh) * 2022-11-09 2024-07-16 美商坦帕斯醫療公司 三唑酮化合物及其用途
WO2025106820A1 (en) * 2023-11-16 2025-05-22 University Of South Florida Method of preventing progesterone contraceptive-induced abnormal uterine bleeding (aub)

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US492839A (en) 1893-03-07 Key for brake-shoes
US528409A (en) 1894-10-30 Denis ahern
US402034A (en) 1889-04-23 Dumping-wagon
US402150A (en) 1889-04-30 Broadcast seed-sower
US402055A (en) 1889-04-23 Water-motor
FR2512732A1 (fr) 1981-09-14 1983-03-18 Raffinage Cie Francaise Procede de fabrication d'objets composes d'un materiau rigide expanse a base de polychlorure de vinyle, objets obtenus par ce procede et leurs applications
US5340585A (en) 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
ECSP961635A (es) 1996-01-11 1997-06-27 Desprendimiento controlado de esteroides del recubrimiento de azucar
ECSP971998A (es) 1997-01-15 1998-04-07 Desprendimiento controlado de esteroides del recubrimiento de azucar
DE19815060A1 (de) 1998-04-03 1999-10-14 Jenapharm Gmbh Pharmazeutische Präparate zur Therapie von Nebenwirkungen während und/oder nach einer GnRHa-Therapie
US6265393B1 (en) * 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
TWI225863B (en) 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
US6297379B1 (en) 1999-03-24 2001-10-02 Takeda Chemical Industries, Ltd. Thienopyrimidine compounds, their production and use
US6849738B2 (en) 2000-02-29 2005-02-01 Takeda Chemical Industries, Ltd. Processes for the production of thienopyrimidine derivatives
WO2003064429A1 (en) 2002-01-30 2003-08-07 Takeda Chemical Industries, Ltd. Thienopyrimidines, process for preparing the same and use thereof
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
CN100424078C (zh) 2003-07-07 2008-10-08 纽罗克里生物科学有限公司 作为促性激素释放激素受体拮抗剂的嘧啶-2,4-二酮衍生物
MY151322A (en) 2004-04-30 2014-05-15 Bayer Ip Gmbh Management of breakthrough bleeding in extended hormonal contraceptive regimens
ES2494842T3 (es) 2005-07-22 2014-09-16 Takeda Pharmaceutical Company Limited Agente que previene la ovulación precoz
TWI386417B (zh) 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
PE20090044A1 (es) 2007-04-06 2009-01-23 Neurocrine Biosciences Inc Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos
US8765948B2 (en) 2007-11-07 2014-07-01 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
WO2010026993A1 (ja) 2008-09-03 2010-03-11 武田薬品工業株式会社 製剤における吸収性改善方法および吸収性が改善された製剤
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
KR20200144591A (ko) 2010-06-16 2020-12-29 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
JP2012077020A (ja) 2010-09-30 2012-04-19 Mochida Pharmaceut Co Ltd ゲスターゲンとＧｎＲＨアンタゴニストとの組合せ医薬
AR092707A1 (es) 2012-09-28 2015-04-29 Takeda Pharmaceuticals Co Metodo de produccion de derivado de tienopirimidina
US10881659B2 (en) * 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
TWI744224B (zh) 2015-02-26 2021-11-01 日商武田藥品工業股份有限公司 固形製劑
AU2016317955B2 (en) 2015-09-01 2021-05-20 Abbvie Inc. Methods of administering Elagolix
ES2912929T5 (en) 2016-09-30 2025-05-09 Sumitomo Pharma Switzerland Gmbh Methods of treating uterine fibroids and endometriosis
MA46361A (fr) 2016-09-30 2021-03-31 Myovant Sciences Gmbh Traitement du cancer de la prostate
EA201992612A1 (ru) 2017-06-05 2020-05-20 Обсева С.А. Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
WO2021069700A1 (en) 2019-10-10 2021-04-15 Myovant Sciences Gmbh Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CA3185151A1 (en) 2020-05-29 2021-12-02 Myovant Sciences Gmbh Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists
WO2022101303A1 (en) 2020-11-11 2022-05-19 Myovant Sciences Gmbh Methods of administering relugolix
JP2024540922A (ja) 2021-10-18 2024-11-06 スミトモ ファーマ スウィッツァーランド ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形

Also Published As

Publication number Publication date
JP2019529575A (ja) 2019-10-17
US20190262346A1 (en) 2019-08-29
HRP20220708T1 (hr) 2022-07-22
HUE072130T2 (hu) 2025-10-28
IL265700A (en) 2019-05-30
IL265700B2 (en) 2023-07-01
WO2018060501A2 (en) 2018-04-05
NZ752916A (en) 2022-09-30
EP3518933A2 (en) 2019-08-07
HUE059101T2 (hu) 2022-10-28
IL265700B1 (en) 2023-03-01
DK3518933T4 (da) 2025-04-22
PL3518933T3 (pl) 2022-06-20
IL300580A (en) 2023-04-01
US20210401841A1 (en) 2021-12-30
ES3018413T3 (es) 2025-05-16
PT3518933T (pt) 2022-05-10
SI3518933T2 (sl) 2025-05-30
CN110312512B (zh) 2023-05-09
LT3518933T (lt) 2022-06-10
CN110312512A (zh) 2019-10-08
AU2022241582B2 (en) 2024-06-13
JP7043503B2 (ja) 2022-03-29
IL300580B1 (en) 2025-07-01
AU2022241582C1 (en) 2024-11-28
EP3518933B1 (en) 2022-03-16
ES2912929T3 (es) 2022-05-30
ES2912929T5 (en) 2025-05-09
AU2017336363B2 (en) 2022-08-04
CA3038879A1 (en) 2018-04-05
SMT202200254T1 (it) 2022-07-21
EP4094766A1 (en) 2022-11-30
CY1125254T1 (el) 2024-02-16
RS63300B2 (sr) 2025-05-30
FI3518933T4 (fi) 2025-05-14
US11033551B2 (en) 2021-06-15
US11957684B2 (en) 2024-04-16
US11793812B2 (en) 2023-10-24
EP4094766B1 (en) 2025-04-02
BR112019006227A2 (pt) 2019-06-18
IL300580B2 (en) 2025-11-01
US20220370462A1 (en) 2022-11-24
MD3518933T4 (ro) 2025-10-31
WO2018060501A3 (en) 2018-05-11
DK3518933T3 (da) 2022-05-30
RS63300B1 (sr) 2022-07-29
US20240165118A1 (en) 2024-05-23
AU2017336363A1 (en) 2019-05-16
AU2022241582A1 (en) 2022-10-27
MD3518933T2 (ro) 2022-07-31
PL4094766T3 (pl) 2025-07-28
SI3518933T1 (sl) 2022-06-30
PL3518933T5 (pl) 2025-05-05
HRP20220708T4 (hr) 2025-04-25
EP3518933B2 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
MX2019003726A (es) Metodos para tratar fibroides uterinos y endometriosis.
Chen et al. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl) phenyl) amino) pyrimidin-2-yl) amino)-4-methoxy-2-(4-methyl-1, 4-diazepan-1-yl) phenyl) acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC
MX2023001468A (es) Tratamiento de cancer de prostata.
NZ745957A (en) Heterocyclic amides useful as protein modulators
AU2010286569A1 (en) Compounds and compositions as protein kinase inhibitors
MX344580B (es) Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa.
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
NZ708563A (en) Treatment of cancers using pi3 kinase isoform modulators
MX2019009501A (es) Compuestos de amino piridina utiles como inhibidores de ssao.
MY203694A (en) Sustained release dosage forms for a jak1 inhibitor
PH12021551290A1 (en) Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
BR112018075206A2 (pt) tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida
MX2019014482A (es) Régimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para tratar miomas uterinos y reducir la menstruación.
MY181349A (en) Oxytocin receptor antagonist therapy in the luteal phase for implantation and pregnancy in women undergoing assisted reproductive technologies
IN2014DN08604A (https=)
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
PE20210096A1 (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret
MX2024007444A (es) Inhibidores de cinasa met.
MX2017014844A (es) Regimen modulador selectivo de los receptores de progesterona (sprm).
EA201990857A1 (ru) Способы лечения миомы матки и эндометриоза
MY188267A (en) Progesterone receptor antagonist dosage form
MA46362B1 (fr) Méthodes de traitement des fibromes utérins et de l'endométriose
EA201990762A1 (ru) Способы лечения женского бесплодия
EA201990057A1 (ru) Схемы применения антагониста окситоцина для содействия имплантации эмбриона и предотвращения выкидыша